Savara Inc (SVRA)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price: $5.30
Day: -2.75%
Market cap: $1.09B

Close 2026-09-22.

The company

Business Overview Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we,” “our” or “us”) is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, molgramostim inhalation solution ("MOLBREEVI " or "molgramostim" ) , is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”). MOLBREEVI is delivered via a proprietary eFlow ® Nebulizer System (PARI Pharma GmbH, “PARI”).

From Item 1: Business Overview.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

NEA Management Company, LLC — $150.74M
Bain Capital Life Sciences Investors, LLC — $108.42M
Venrock Adviser, LLC — $90.84M
DEERFIELD MANAGEMENT COMPANY, L.P. — $83.59M
TCG Crossover Management, LLC — $76.15M
Frazier Life Sciences Management, L.P. — $59.88M
Polar Capital Holdings Plc — $58.78M
VANGUARD CAPITAL MANAGEMENT LLC — $48.86M

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Lowrance David L (Chief Financial Officer) sold 394,528 shares at $5.68 on 2026-06-22
RAMSAY DAVID A (Director) sold 20,000 shares at $6.06 on 2025-12-19
Hawkins Richard J (Director) bought 48,225 shares at $2.04 on 2025-06-20
McCracken Joseph S (Director) bought 10,000 shares at $2.08 on 2025-05-29
RAMSAY DAVID A (Director) bought 150,000 shares at $2.78 on 2025-03-31
Lowrance David L (Chief Financial Officer) sold 25,000 shares at $3.33 on 2024-12-16

Recent filings

S-8 — 2026-08-11
10-Q — 2026-08-11
4 — 2026-07-24
4 — 2026-06-22
144 — 2026-06-22
8-K — 2026-06-08
10-Q — 2026-05-12
ARS — 2026-04-24
DEF 14A — 2026-04-24
DEFA14A — 2026-04-24